Pharmaceutical Investing TG Therapeutics Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib
Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
